Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Multiepitope CD8+ T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting
Valérie Dutoit, Robert N. Taub, Kyriakos P. Papadopoulos, Susan Talbot, Mary-Louise Keohan, Michelle Brehm, Sacha Gnjatic, Paul E. Harris, Brygida Bisikirska, Philippe Guillaume, Jean-Charles Cerottini, Charles S. Hesdorffer, Lloyd J. Old, Danila Valmori
Valérie Dutoit, Robert N. Taub, Kyriakos P. Papadopoulos, Susan Talbot, Mary-Louise Keohan, Michelle Brehm, Sacha Gnjatic, Paul E. Harris, Brygida Bisikirska, Philippe Guillaume, Jean-Charles Cerottini, Charles S. Hesdorffer, Lloyd J. Old, Danila Valmori
View: Text | PDF
Article Immunology

Multiepitope CD8+ T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting

  • Text
  • PDF
Abstract

Research Article

Authors

Valérie Dutoit, Robert N. Taub, Kyriakos P. Papadopoulos, Susan Talbot, Mary-Louise Keohan, Michelle Brehm, Sacha Gnjatic, Paul E. Harris, Brygida Bisikirska, Philippe Guillaume, Jean-Charles Cerottini, Charles S. Hesdorffer, Lloyd J. Old, Danila Valmori

×

Figure 2

Options: View larger image (or click on image) Download as PowerPoint
Sarcoma patients vaccinated with NY-ESO-1 peptides 157-165 and 157-167 r...
Sarcoma patients vaccinated with NY-ESO-1 peptides 157-165 and 157-167 respond to distinct overlapping A2-restricted epitopes in the 157-167 region. Polyclonal monospecific CD8+ multimer+ populations were isolated by cell sorting with the corresponding multimers and further expanded in vitro by mitogen-driven stimulation. After 2 weeks of in vitro expansion, each population was stained with multimers incorporating each of the overlapping 9-mer and 10-mer in the 157-167 region.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts